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Gas discharge plasmas formed at atmospheric pressure and near room temperature have recently
been shown as a promising tool for cancer treatment. The mechanism of the plasma action is
attributed to generation of reactive oxygen and nitrogen species, electric fields, charges, and
photons. The relative importance of different modes of action of atmospheric-pressure plasmas
depends on the process parameters and specific treatment objects. Hence, an in-depth understand-
ing of biological mechanisms that underpin plasma-induced death in cancer cells is required to
optimise plasma processing conditions. Here, the intracellular factors involved in the observed
anti-cancer activity in melanoma Mel007 cells are studied, focusing on the effect of the plasma
treatment dose on the expression of tumour suppressor protein TP73. Over-expression of TP73
causes cell growth arrest and/or apoptosis, and hence can potentially be targeted to enhance killing
efficacy and selectivity of the plasma treatment. It is shown that the plasma treatment induces
dose-dependent up-regulation of TP73 gene expression, resulting in significantly elevated levels of
TP73 RNA and protein in plasma-treated melanoma cells. Silencing of TP73 expression by means
of RNA interference inhibited the anticancer effects of the plasma, similar to the effect of caspase
inhibitor z-VAD or ROS scavenger N-acetyl cysteine. These results confirm the role of TP73 pro-
tein in dose-dependent regulation of anticancer activity of atmospheric-pressure plasmas. VC 2015
AIP Publishing LLC. [http://dx.doi.org/10.1063/1.4933366]
I. INTRODUCTION
Non-equilibrium gas discharge plasmas formed at
atmospheric pressure and near room temperature plasmas
have been attracting interest for their demonstrated ability to
inactivate pathogenic microorganisms, promote tissue heal-
ing, and selectively induce apoptosis in cancer cells.1–9 The
biological activity of such plasma treatment stems from a
combination of plasma-induced chemical and physical proc-
esses, including contributions from electric field, ultraviolet
radiation, overpressure shock waves, and formation of vari-
ous reactive chemical species such as radicals and molecular
species, although their exact contributions toward overall
treatment efficacy remains poorly understood.10
In general, thermal and electric effects that lead to direct
denaturing of the target cells and tissues are minimised in
favour of chemistry-driven responses,11 with the nature and
level of highly reactive chemistry, in particular, reactive oxy-
gen and nitrogen species (RONS) deciding the fate of cells.
In cancer medicine, this chemistry-specific approach enables
selective killing of cancer cells with limited side effects on
normal cells.12–16 Indeed, current research in the area shows
that unlike conventional anti-cancer drugs, such as eribulin
or cabazitaxel,17 plasma treatment can be effective in induc-
ing programmed cell death (apoptosis), in a broad range of
cancer cell types in vitro and in vivo, with no evidence of
normal cell death.15,16,18–20
The nature and relative concentration of chemical spe-
cies generated in plasmas vary greatly between plasma sys-
tems and as a function of processing parameters, such as
pressure, background gas composition, operating frequency
and power, and whether they are produced in solution, in
air or at the gas/solution interface. In solutions, plasmas
induce the formation of hydroxyl radical OH•, ozone (O3),
and hydrogen peroxide (H2O2), which then drive the
plasma-induced changes in molecules and cells via oxida-
tion. In atmospheric-pressure plasmas, the interactions
between the plasma and the air results in partial dissocia-
tion and ionization of ambient O2, N2, and H2O, giving rise
to biologically relevant levels of species capable of induc-
ing specific intracellular responses. These include oxygen
species, e.g., O3, singlet delta oxygen (O2 a
1Dg), H2O2,
OH•, and nitrogen species, e.g., atomic nitrogen (N), nitro-
gen oxides (e.g., NO, NO2, and N2O), peroxynitrite
(ONOO), nitric and nitrous acid (HNO3, HNO2), and sev-
eral others. When plasma is generated at gas/solution inter-
face, the produced reactive species diffuse into the solution,
where they engage into chemical reactions with treated
cells or biomolecules. While ions tend to recombine in the
vicinity of the visible plasma plume, neutral species can
travel significantly further. In addition to oxidation, reduc-
tion induced by H• and superoxide radicals and molecular
hydrogen can contribute to the plasma-induced change.
a)Author to whom correspondence should be addressed. Electronic mail:
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Many of these chemical species play critical roles in the
biology of normal and cancer cells.21 However, their signifi-
cance in inducing specific intracellular biochemical events as
part of plasma-cell interactions is not well understood.22 The
balance of the species has been shown to yield very specific
biological outcomes,15 inducing differentiation in stem cells
in NO-rich acidic solutions and killing effect in basic ROS-
rich solutions.23
The biological outcome strongly depends on the dose of
the plasma exposure, from stimulating cell proliferation at
low doses to inducing apoptosis (controlled cell death), and
finally, necrosis (uncontrolled cell death) as the dose is
increased.24 The dose is broadly defined by the energy used
to generate the plasma, the length of the treatment, and the
proximity of the plasma glow to the treatment zone. It is im-
portant to note that not all the energy used to generate the
plasma is transferred to the species that actually interact with
the surface of biological objects.
However, since there is still no clear understanding of
which plasma effects are most biologically relevant, the dose
does not reflect the quantity of specific chemical species or
physical effects required to achieve the desired biological
responses. This impedes translation of plasma antitumor
treatments from laboratory to clinical applications.
Equally hindering is the lack of understanding regarding
the intracellular processes that take place upon plasma expo-
sure, which limits our ability to optimise the treatment pro-
cess. Our previous work on atmospheric gas plasma
treatment of melanoma and healthy melanocyte cells12 dem-
onstrated selective induction of apoptosis in cancer cells and
described one of the mechanisms by which apoptosis was
achieved (the oxidative stress–induced TNF-ASK1-JNK/
p38–caspase-3/7 apoptotic pathway).
The aim of this article is to further explore the intracel-
lular factors involved in the observed anti-cancer activity of
non-equilibrium atmospheric-pressure plasmas, and to intro-
duce some of the key biological mechanisms involved in
plasma-cancer cell interaction. This article reports on the
effect of plasma treatment dose on the expression of tumour
suppressor protein TP73 in melanoma Mel007 cells. TP73 is
a member of the p53 family of proteins that are known to
induce cell cycle arrest and apoptosis in cancer cells.25–29
II. MATERIALS AND METHODS
A. Atmospheric-pressure plasma jet
All cells were treated with atmospheric-pressure plasma
plume, which was generated using a custom-designed atmos-
pheric-pressure plasma jet device as shown in Figure 1 and
described in detail previously.12 Briefly, the device consists
of a fused quartz tube equipped with two conducting electro-
des. One electrode is a metal wire placed inside the tube
along tubal-axis, finishing 1.8 cm before the nozzle exit.
The second electrode is a metal ring attached to the outer
wall of the tube near the nozzle exit. The apparent distance
between the two electrodes is 1.0 cm. Helium gas is flown
through the quartz tube at 2 l/min. A non-equilibrium plasma
discharge is produced between the two electrodes by an
applied AC high voltage. The high voltage is generated by
an RF power source coupled with an RF voltage amplifier.
The cells treatment is conducted at the discharge voltage and
operating frequency between 1.1–1.8 kV and 230–270 kHz,
respectively.
The plasma discharge produced at the end of the metal
wire electrode is located in two different spatial regions. One
part of the discharge is located entirely inside the tube, from
the end of the metal wire electrode to the ring electrode,
and part of the discharge from the ring electrode propagates
along with the gas flow and extends out of the tube through
the nozzle as a collimated plasma jet. Under selected
treatment conditions, the length of the plasma jet exceeds
2.5 cm,30,31 with the end diameter of this collimated plasma
jet at 500 lm. This plasma jet is considered a cold plasma
due to the measured low gas temperature (35–40 C).
During the discharge process, electrical parameters of
the plasma, such as discharge voltage and current, are moni-
tored using high- and low-voltage probes, respectively. The
discharge current between the metal wire and the ring elec-
trodes is 10 mA. However, only 5%–10% of this current is
likely to extend out of the discharge tube, which is used for
cell treatment.32
B. Cell treatment and characterisation
The human melanoma cell line Mel007 was provided by
Peter Hersey, Melanoma Institute, University of Sydney33
and were maintained in DMEM media (Invitrogen) plus 10%
FBS. Caspases inhibitor Z-VAD-FMK (C#G7231) and ROS
scavenger N-acetylcysteine amide (NAC) (C#A0737) were
purchased from Sigma Aldrich.
To estimate cell viability, cells were cultured in 96-well
plates at 2 104 cells/well overnight, treated with atmos-
pheric gas plasma for indicated time periods (5, 10 and 15 s),
and incubated for 18–24 h. Cell viability was measured using
CellTiter 96 Aqueous Non-Radioactive Cell proliferation
FIG. 1. Schematic of the atmospheric-pressure plasma jet device for cell
treatment.
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(MTS) Assay (Promega, C#G5421) following the protocol
provided by the manufacturer. In some experiments, the
caspase inhibitor zVAD-FMK (50 lM) or NAC (3mM) was
added 1–2 h prior to atmospheric gas plasma treatment.
NAC is an important antioxidant commonly used to identify
and test ROS inducers and the role of ROS species in cell
death. The antioxidative or free radical scavenging property
of NAC stems from its ability to increase intracellular levels
of an important natural antioxidant glutathione (for which
NAC is a synthetic precursor), and through its reducing
thiol-disulfide exchange activity.34 Pan-caspase inhibitor
zVAD-FMK selectively inhibits caspases 3 and 7, and hence
is commonly used to test whether observed cell death was
attributed to caspase-dependent apoptosis. Assays were per-
formed in triplicate.
To evaluate changes in cell gene expression as a result of
atmospheric-pressure plasma treatment, a quantitative real-
time polymerase chain reaction technique was used. Cells
were cultured in 6-well plates at 5 105 cells/well overnight,
treated with atmospheric-pressure plasma for specified time
periods, and incubated for 18–24 h. Following incubation,
total cell RNA was extracted using Trizole reagent
(Invitrogen, C#15596–026) and reverse transcribed into
single-stranded cDNA following the procedure described pre-
viously.35 Quantitative relative gene expression was deter-
mined using SsoAdvanced SYBR Green SuperMix (Biorad,
C#172–5265) with Roche Lightcycler 480 qPCR system.
Data were analysed with LightCycler 480 software. The
human p53 PCR array primers library (RealTimePCR.com,
C#HTPS-1) was used to quantify relative gene expression of
>90 genes involved in p53 signalling pathways. GAPDH,
Actin-b, GUS-b, B2M, HPRT1, PPIA, and RPL13A were
used as internal controls to normalize data. Relative quantifi-
cation of gene expression after atmospheric gas plasma treat-
ment was obtained by using the DCT method compared to
fold change of untreated (He gas flow only) control cells.
For RNA interference and Western Blot analyses, cells
grown to a density of 70% confluence with antibiotic-free
media were transfected with the TP73 siRNA (Santacruz,
C#sc-43730) and negative control siRNA by lipofectamine
(Invitrogen) according to the manufacturer’s instructions.
After 24 h of siRNA transfection, cells were treated with
atmospheric gas plasma. Cells were harvested and lysed in
RIPA lysis and extraction buffer (C#89901), halt protease in-
hibitor cocktail (C#87786), and halt phosphatase inhibitor
cocktail (C#78420) (thermoscientific) by incubating on ice
for 30min, as described previously.36
Protein concentration was determined by BCA protein
assay kit (Thermoscientific, C#23227). After adding 2 SDS
loading buffer, the samples were subjected to SDS-PAGE
(Biorad, MP TGX 4%–20%, C#4561094). Protein was then
transferred onto immunoblot polyvinylidene fluoride mem-
brane (Millipore, Billerica, MA) and probed with the pri-
mary antibodies as specified and horseradish-conjugated
secondary antibodies. The bonded proteins were visualized
with a chemiluminescence detection kit (Biorad, Clarity
western ECL substrate C#170–5060) using ImageQuant
LAS400 (GE technology). GAPDH antibodies and TP73
(sc-9651) antibodies were purchased from Cell Signaling
Technology and Santa Cruz Biotechnology, respectively.
III. RESULTS AND DISCUSSION
Cancer is a complex disorder that involves the alteration
of intracellular homeostasis by a series of genetic muta-
tions.37 In normal cells, there are a number of mechanisms to
ensure that DNA mutations are not passed along to daughter
cells, either through error correction (by arresting the cell
cycle until the error is fixed) or by destroying the cell
(through programmed cell death). Programmed cell-death is
a general term used to denote death of a cell mediated by an
intracellular program. Apoptosis is the process of pro-
grammed cell death, where intracellular biochemical events
lead to characteristic cell changes, such as cell shrinkage, nu-
clear fragmentation, chromatin condensation, and chromo-
somal DNA fragmentation, and eventually cell death. Other
programmed cell-death types include autophagy, a catabolic
process associated with autophagosomic-lysosomal degrada-
tion of bulk cytoplasmic contents, abnormal protein aggre-
gates, and excess or damaged organelles; necroptosis, where
caspase-independent inflammatory cell death (necrosis) is
initiated in a programmed fashion; anoikis, where cell death
is induced by anchorage-dependent cells detaching from the
surrounding extracellular matrix; excitotoxicity, where neu-
ron cell death is induced by overstimulation with glutamate
or related excitatory amino acids; ferroptosis, an iron-
dependent form of cell death; Wallerian degeneration; and
potentially others.
In cancer cells, these mechanisms are often compro-
mised, with mutations passed along to subsequent genera-
tions. Plasma treatment provides the means to selectively
induce apoptosis in cancer cells, potentially via activation of
different tumour suppressors and inhibition of various onco-
genes, without harming the healthy cells.22 This selectivity is
highly desired, as most current cancer therapies tend to at
least to some degree damage healthy cells. The apoptotic na-
ture of atmospheric plasma-induced cell death is demon-
strated using Annexin V/propidium iodide apoptosis assay
that can differentiate between viable, apoptotic, or necrotic
cells through differences in plasma membrane integrity and
permeability.7,38
Apoptosis is a genetically regulated biological process
with two pathways: the death-receptor-induced extrinsic path-
way and the mitochondria-apoptosome-mediated intrinsic
pathway. The Bcl-2 family has a central role in controlling the
mitochondrial pathway.39 Yan et al. have shown that Bcl-2
family members are involved in atmospheric plasma-induced
apoptosis. Atmospheric gas plasma treatment induced expres-
sion of Bax and inhibited Bcl-2 expression determined the
involvement of mitochondrial-mediated apoptotic pathway.40
In human embryonic kidney 293T cells, nitrogen plasmas acti-
vated a surrogate DNA damage signal transduction pathway,
called the ataxia telangiectasia mutated (ATM)-checkpoint
kinase 2 pathway; this effect suggests that the nitrogen plasma
induced DNA double-strand breaks. Phosphorylation of
H2AX and p53 was detected in the plasma-treated cells lead-
ing to apoptotic cell death.41,42 Human colorectal cancer cells
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treated with non-thermal He/O2 atmospheric plasmas experi-
enced cell growth arrest and apoptosis.43 This treatment
reduced the cell migration and invasion activities and also
increased beta-catenin phosphorylation that might play a role
at least in part in the plasma-induced anti-proliferative activ-
ity.43 It has been recently shown that the plasmas can specifi-
cally disable S-phase of the cell cycle in skin cancer cells.
This effect was not observed in control cells demonstrating
the plasma selectively induced apoptosis in cancer cells.44
Plasma can often act synergistically in combination with
other objects, such as nanoparticles and other drugs, by
reducing the minimum inhibition concentration of nanopar-
ticles or drug and hence reducing toxicity of the treat-
ment.45,46 The synergy between plasma and nanoparticles
for anticancer therapy can potentially be extended to the
plasma-assisted fabrication of porous nanostructures that can
be used to trap plasma-generated ROS/RNS species, to
extend their half-life and ensure their passage deep into
affected tissues, as well as facilitate the use of less chemi-
cally reactive materials in nanoparticle synthesis.
Nanoparticles prepared in an atmospheric plasma jet can be
both exposed to very high concentrations of ROS/RNS and
simultaneously charged to facilitate their directional penetra-
tion into tissues.45,47,48 Mutual orientation of plasma ion
fluxes and nanoarrays can further enable nanoparticles to tar-
get specific cellular sites. Another potential avenue involves
pre-deposition of nanoparticles onto specific surface sites of
cell membrane to form a cell-surface mask for spatially
selective plasma treatment.
To ensure that plasma treatment is tuned for optimum
selectivity and killing efficacy, it is critical to understand the
biological processes that take place within the cell upon
plasma exposure. The genetic manipulation of tumour cells
to express or inhibit tumour-inducing or tumour-suppressing
molecules provides a means to analyse cellular responses
against tumourigenesis and anti-tumour therapeutics, such as
plasma treatment. To explore possible signalling cascades
involved in the plasma-induced cancer cell death, we quanti-
fied some of the key signalling genes involved in apoptosis.
In this work, we explored the effect of plasma treatment
dose on the expression of tumour suppressor protein TP73,
which, when overexpressed, is known to cause a growth
arrest and/or apoptosis, and hence can potentially be targeted
to enhance killing efficacy and selectivity of plasma treat-
ment. TP73 belongs to the tumour protein p53 family. The
p53 pathway responds to stresses that can disrupt the fidelity
of DNA replication and cell division, with tumour protein
p53 having many mechanisms of anticancer function, includ-
ing apoptosis, genomic stability, and inhibition of angiogen-
esis. In a healthy cell, p53 is inactivated by its negative
regulator, mdm2. This occurs through the direct binding of
mdm2 to the N-terminal end of p53, which inhibits the tran-
scriptional activation function of p53, and through E3 ubiq-
uitin ligase activity of mdm2, which targets p53 for
modification and subsequent degradation through the 26S
proteasome.49 DNA damage or stress can initiate the physi-
cal dissociation of the p53 and mdm2 complex via a number
of pathways. Activated p53 can induce cell cycle arrest (to
enable DNA repair) or apoptosis.
A. Effect of plasma dose on tumour suppressor p53
cell signalling pathway
To explore possible signalling cascades involved in the
plasma-induced cancer cell death, some of the key signalling
genes (selected 85 genes as shown in Figure 2) involved in
p53 signalling pathway were quantified by qPCR (presented
and briefly described in Materials and Methods). As shown
in Figure 2, BTG2, Casp2, Casp9, CCNB2, CDKN1A,
IFNB1, PPKCA, PTEN, and TP73 were among the
FIG. 2. The results of qPCR analysis performed for the key 85 signalling genes involved in p53 signalling pathway. qPCR data were normalized; bars indicate
the standard error of the mean, statistical analysis by t-test.
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differentially expressed genes in melanoma Mel007 cells
treated with atmospheric gas plasma.
Among them, the tumour suppressor protein TP73 gene
was the most induced gene (up to 70 fold) compared to con-
trol untreated cells. Structurally, TP73 protein shares the
same architecture with p53, with a significant identity in pri-
mary sequence, especially in DNA-binding domain and, to
lesser extent in the transactivation domain which has pro-
apoptotic effects.28,50 As a result, TP73 is able to transacti-
vate several p53 responsive genes involved in the control of
cell cycle arrest and apoptosis.25 Similar to p53, TP73 shows
multiple distinct splicing isoforms (at least seven), with a
resulting complicated array of functional effects.51
These gene screening results demonstrate the impor-
tance of p53 family members, particularly high expression of
TP73 in plasma-induced cancer cell death. This is consistent
with previous reports that implicated TP73 in inducing apo-
ptosis in cells with DNA damage via different signalling
pathways.52–55 Up-regulation of TP73 (and apoptosis) has
been observed in response to various DNA-damaging
agents.26 The mechanisms by which TP73 can induce apo-
ptosis in cancer cells involve induction of G1 cell growth,
arrest and activation, the transcription of some endogenous
p53 target genes, such as 14-3-3r, mdm2, cyclin G,
p21Waf1/Cip1, GADD45, ribosomal gene cluster (RGC),
Bax, and insulin-like growth factor-binding protein 3 (IGF-
BP3).27,28 Additionally, TP73 can induce apoptosis by acti-
vating PUMA/Bax signaling, where TP73 directly activates
PUMA transactivation activity. The direct effect of PUMA
on Bax promoter suggests a molecular link between TP73
and the mitochondrial apoptotic pathway.29
To further study the effect of atmospheric gas plasma
treatment on cancer cells and TP73 gene expression at RNA
and protein level, melanoma Mel007 cells were treated for 5,
15, or 30 s (to vary the plasma dose). Figures 3(a) and 3(b)
show the plasma increased TP73 RNA and protein expres-
sion in dose-dependent manner. Given that larger plasma
doses (e.g., longer treatment times) are also associated with
higher rate of cell death, the involvement of TP73 tumour
suppressor protein in plasma-induced cancer cells death is
likely.
B. Plasma-induced melanoma cells death in TP73
dependent manner
The specific effects of TP73 in plasma-induced cancer
cell death were also explored. RNA interference (RNAi) spe-
cific to TP73 (TP73 siRNA) were used to knockdown the
TP73 gene at RNA level. Gene knockdown, also known as
gene silencing, describes the regulation of gene expression,
where the expression of a certain gene is reduced but not
completely eliminated. The reduced expression is achieved
by interfering with either transcription (a process of copying
a particular segment of DNA into RNA) or translation (a pro-
cess of decoding of RNA by a ribosome to produce a specific
polypeptide) stages of gene expression. Gene knockdown is
commonly used in research to evaluate the significance of a
particular protein in the observed intracellular processes.
As shown in Figure 4(a), TP73 siRNA treatment specifi-
cally inhibited TP73 protein expression in Mel007 cancer
cells. To further confirm the role of TP73 in plasma-induced
cancer cell death, siRNA-pre-treated Mel007 cells were sub-
jected to plasma treatment. Cell viability assay showed that
FIG. 3. Effects of the atmospheric-pressure plasma treatment on TP73 gene
expression at RNA and protein level in melanoma Mel007 cells as a function
of the plasma treatment time. (a) Quantification of TP73 gene expression
using qPCR. (b) Western Blot analysis. Mouse IgG1 isotype antibody was
used as negative control. GAPDH expression was used as loading control.
FIG. 4. (a) TP73 specific siRNA pre-treatment specifically inhibited TP73
protein expression in Mel007 cancer cells. (b) Cell viability assay showed
that knockdown of TP73 by TP73 specific siRNA in cancer cells inhibited
plasma-induced cytotoxic effects, similar to the effect of pre-treatment with
caspase inhibitor zVAD and ROS scavenger NAC.
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knockdown of TP73 by TP73 specific siRNA in cancer cells
inhibited plasma-induced cytotoxic effects (Figure 4(b)).
The effect of TP73 silencing was similar to that of inter-
fering with either TNF receptor 1 (using antagonist–neutraliz-
ing antibody vZAD) or intracellular ROS levels (using ROS
scavenger N-acetyl-l-cysteine), or depletion of intracellular
ASK1. In our previous work, we confirmed the oxidative
stress-induced TNFASK1JNK/p38–caspase-3/7 apoptotic
pathway as one of the possible mechanisms for atmospheric
gas plasma activation and regulation of apoptosis-signalling
pathways in tumour cells. Briefly, extracellular ROS gener-
ated by plasma induce oxidative stress.
In response to this stress, the intrinsic mitochondrial
pathway of apoptosis is induced, with increased expression
of apoptosis signal molecules, primarily tumour necrosis fac-
tors (TNFs), and activation of apoptosis signal-regulating ki-
nase 1 (ASK1) pathway. ASK1 is a mitogen-activated
protein kinase (MKK) that is activated by various stress-
related stimuli, including oxidative stress, ROS, genotoxic
agents, endoplasmic reticulum stress, and TNFs.
Intracellular ROS and ROS generated by TNFs disso-
ciate a redox regulatory protein (thioredoxin, Trx)
that inhibits the kinase activity of ASK1. The activated
ASK1 phosphorylates and activates the downstream ki-
nases MKK4/MKK7 and MKK3/MKK6. The initiation of
these pathways increases downstream activity of c-Jun
N-terminal (JNK) and p38 mitogen-activated protein ki-
nases and stimulate activation of cysteine-dependent aspar-
tate-specific proteases (caspase 3 and 7). These caspases
proteolytically degrade a host of intracellular proteins,
resulting in cellular shrinkage and DNA fragmentation,
culminating in apoptosis.
Taken together, the results suggest that multiple signal-
ling pathways mediate plasma-induced melanoma cells death,
with tumour suppressor protein TP73 playing a notable role
in plasma-induced apoptosis. The precise mechanisms by
which plasma treatment induces TP73 up-regulation and how
these events lead to melanoma cancer cell apoptosis need to
be elucidated.
IV. CONCLUSION
This work represents an initial step in the studies of the
effects of non-equilibrium, low-temperature atmospheric-
pressure plasmas on melanoma Mel007 cancer cells. One of
the marked effects noted through the gene expression analy-
sis of >90 genes involved in p53 signalling pathways is a
clear up-regulation of tumour suppressor protein TP73. This
study has revealed the effect of the plasma dose on the
expression of TP73. Silencing of TP73 synthesis inhibited
the anticancer effects of plasma. Importantly, anticancer effi-
cacy of atmospheric-pressure plasma treatment is affected by
the activity of the tumour suppressor protein TP73, which in
turn can be plasma-dose dependent. Even though these
results are obtained for the specific type of cancers, they
nevertheless suggest that similar intracellular mechanisms
may be deliberately induced by controlling the plasma expo-
sure to halt or even reverse development of cancer in other
cell types.
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